Vanessa Broadhurst
Known title: DirectorCIK: 0001904787
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Goldman Sachs initiates Zoetis coverage with Neutral rating. Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.
Transaction History
| JNJ | ▲ Buy | Option Exercise | 11,129 | $1.4M | 7/20/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 11,925 | $1.6M | 7/20/2026 | View on chart |
| JNJ | ▼ Sell | Open Market | 23,054 | $5.8M | 7/20/2026 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,619 | — | 2/19/2026 | View on chart |
| ZTS | ▼ Sell | Other | 517 | $66K | 2/19/2026 | View on chart |
| JNJ | ▼ Sell | Open Market | 6,197 | $1.5M | 2/17/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 492 | $0 | 2/15/2026 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 252 | $61K | 2/15/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 526 | $0 | 2/15/2026 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 270 | $66K | 2/15/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 408 | $0 | 2/13/2026 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 144 | $35K | 2/13/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 8,594 | $0 | 2/13/2026 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 3,748 | $917K | 2/13/2026 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,412 | — | 7/25/2025 | View on chart |
| ZTS | ▼ Sell | Other | 451 | $69K | 7/25/2025 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 158 | $25K | 2/18/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 492 | $0 | 2/15/2025 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 151 | $23K | 2/14/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 1,830 | $0 | 2/14/2025 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 574 | $90K | 2/14/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 2,910 | $0 | 2/14/2025 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 997 | $156K | 2/14/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 408 | $0 | 2/13/2025 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,236 | — | 2/6/2025 | View on chart |
| ZTS | ▼ Sell | Other | 395 | $69K | 2/6/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 9,809 | $0 | 7/8/2024 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 5,018 | $738K | 7/8/2024 | View on chart |
| JNJ | ▼ Sell | Open Market | 8,891 | $1.4M | 3/13/2024 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 209 | $33K | 2/13/2024 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 408 | $0 | 2/13/2024 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 4,701 | $0 | 2/12/2024 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 2,136 | $336K | 2/12/2024 | View on chart |
| JNJ | ▲ Buy | Grant | 790 | $0 | 2/12/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,493 | — | 2/8/2024 | View on chart |
| ZTS | ▼ Sell | Other | 477 | $93K | 2/8/2024 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 1,880 | $0 | 2/8/2024 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 703 | $110K | 2/8/2024 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 1,440 | $233K | 2/13/2023 | View on chart |
| JNJ | ▲ Buy | Grant | 3,981 | $0 | 2/13/2023 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 1,592 | $0 | 2/10/2023 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 597 | $97K | 2/10/2023 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 2,557 | $0 | 2/15/2022 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 925 | $153K | 2/15/2022 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 2,451 | $0 | 2/14/2022 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 902 | $152K | 2/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Johnson & Johnson: Key Takeaways for Long-Term Investors
Recent coverage highlighted three takeaways for long‑term investors in Johnson & Johnson. The article notes the company's steady dividend yield of about 3.1% and its diversified healthcare portfolio. It also points to a relatively high price‑to‑earnings multiple, suggesting expectations of continued growth. These points are relevant as the stock trades near a long‑standing support level.
Johnson & Johnson: Key Takeaways for Long-Term Investors. Recent coverage highlighted three takeaways for long‑term investors in Johnson & Johnson. The article notes the company's steady dividend yield of about 3.1% and its diversified healthcare portfolio. It also points to a relatively high price‑to‑earnings multiple, suggesting expectations of continued growth. These points are relevant as the stock trades near a long‑standing support level.